The global polymyalgia rheumatica treatment market attained a value of about USD 203.73 million in 2023. The market is further expected to grow in the forecast period of 2024-2032 at a CAGR of 4.7% to reach nearly USD 308.68 million by 2032. This blog post will delve into various aspects of the polymyalgia rheumatica treatment market, providing an in-depth analysis of its dynamics, trends, segmentation, growth prospects, recent developments, market scope, and the impact of COVID-19.
Polymyalgia Rheumatica Treatment Market Overview
Polymyalgia rheumatica (PMR) is an inflammatory disorder that causes muscle pain and stiffness, particularly in the shoulders and hips. It primarily affects older adults and can significantly impact the quality of life. The treatment market for PMR includes a range of medications aimed at reducing inflammation and alleviating symptoms.
Key Market Drivers
- Aging Population: With the increasing global population of older adults, the prevalence of polymyalgia rheumatica is rising, driving demand for effective treatments.
- Advancements in Medical Research: Continuous research and development activities in the field of rheumatology are leading to the introduction of new and more effective treatments.
- Increased Healthcare Awareness: Growing awareness about PMR and its symptoms is prompting more people to seek medical attention, thereby expanding the market.
Market Restraints
- Side Effects of Medications: Long-term use of corticosteroids, the primary treatment for PMR, can lead to significant side effects, which may hinder market growth.
- High Cost of Treatment: The high cost associated with PMR treatment can be a barrier, particularly in low- and middle-income countries.
Get a Free Sample Report with Table of Contents –https://www.expertmarketresearch.com/reports/polymyalgia-rheumatica-treatment-market/requestsample
Polymyalgia Rheumatica Treatment Market Dynamics
The polymyalgia rheumatica treatment market is influenced by various factors that shape its growth trajectory. Understanding these dynamics is crucial for stakeholders to make informed decisions.
Demand and Supply Dynamics
- Demand Side: The increasing prevalence of PMR and rising awareness about the disease are key factors driving demand. Additionally, the development of more effective and safer medications is also contributing to market growth.
- Supply Side: Pharmaceutical companies are focusing on expanding their product portfolios to include innovative PMR treatments. The availability of advanced diagnostic tools is also facilitating the early diagnosis and treatment of PMR.
Technological Advancements
Technological advancements in the field of rheumatology are playing a pivotal role in the treatment of PMR. The development of biologics and targeted therapies has revolutionized the treatment landscape, offering new hope to patients who do not respond well to traditional therapies.
Regulatory Environment
The regulatory environment for PMR treatments varies across regions. Stringent regulations in developed countries ensure the safety and efficacy of medications, while less stringent regulations in developing regions may pose challenges for market entry.
External Polymyalgia Rheumatica Treatment Market Trends
Several external trends are shaping the polymyalgia rheumatica treatment market. These trends include:
Increasing R&D Investments
Pharmaceutical companies are investing heavily in research and development to discover new treatments for PMR. This trend is expected to continue, leading to the introduction of more effective and safer medications.
Collaborations and Partnerships
Collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare providers are becoming increasingly common. These collaborations are aimed at accelerating the development of new treatments and improving patient outcomes.
Patient-Centric Approaches
There is a growing emphasis on patient-centric approaches in the treatment of PMR. Healthcare providers are focusing on personalized treatment plans that cater to the specific needs of individual patients.
Digital Health Technologies
The integration of digital health technologies, such as telemedicine and mobile health apps, is enhancing the management of PMR. These technologies enable patients to monitor their symptoms and communicate with healthcare providers remotely, improving access to care.
Polymyalgia Rheumatica Treatment Market Segmentation
The polymyalgia rheumatica treatment market can be segmented based on several criteria, including drug type, route of administration, distribution channel, and region.
By Drug Type
- Corticosteroids: Prednisone is the most commonly prescribed corticosteroid for PMR treatment. Other corticosteroids include methylprednisolone and prednisolone.
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs such as ibuprofen and naproxen are used to relieve pain and inflammation.
- Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate is sometimes used in patients who do not respond well to corticosteroids.
- Biologics: Biologic agents like tocilizumab are being explored for their potential in treating PMR.
By Route of Administration
- Oral: The most common route for administering corticosteroids and NSAIDs.
- Injectable: Injectable forms of corticosteroids and biologics are also used in certain cases.
By Distribution Channel
- Hospitals: Hospitals are the primary distribution channel for PMR treatments, particularly for severe cases.
- Retail Pharmacies: Retail pharmacies play a significant role in the distribution of oral medications.
- Online Pharmacies: The rise of online pharmacies is providing patients with convenient access to medications.
By Region
- North America: North America is the largest market for PMR treatments, driven by a high prevalence of the disease and advanced healthcare infrastructure.
- Europe: Europe is another significant market, with a large aging population and increasing awareness about PMR.
- Asia-Pacific: The Asia-Pacific region is expected to witness the fastest growth, owing to rising healthcare investments and improving diagnostic capabilities.
- Latin America: The market in Latin America is growing steadily, supported by increasing healthcare expenditure.
- Middle East and Africa: The market in this region is relatively small but is expected to grow as healthcare access improves.
Polymyalgia Rheumatica Treatment Market Growth
The polymyalgia rheumatica treatment market is poised for significant growth over the forecast period. Several factors contribute to this growth:
Increasing Prevalence of PMR
The aging global population is leading to a rise in the prevalence of PMR. As the population of older adults increases, so does the number of individuals diagnosed with PMR, driving demand for treatments.
Advancements in Treatment Options
Advancements in medical research are leading to the development of new and more effective treatments for PMR. The introduction of biologics and targeted therapies is expected to drive market growth.
Rising Healthcare Expenditure
Rising healthcare expenditure in both developed and developing regions is facilitating better access to PMR treatments. Governments and private sector players are investing in healthcare infrastructure, improving the diagnosis and treatment of PMR.
Growing Awareness
Increasing awareness about PMR and its symptoms is prompting more individuals to seek medical attention. Public health campaigns and educational initiatives are playing a crucial role in raising awareness.
Improved Diagnostic Capabilities
Advancements in diagnostic tools are enabling early and accurate diagnosis of PMR. Early diagnosis is crucial for effective treatment and better patient outcomes.
Recent Developments in the Polymyalgia Rheumatica Treatment Market
New Drug Approvals
The market has witnessed several new drug approvals in recent years. These new treatments are offering better efficacy and safety profiles, providing patients with more options.
Research and Clinical Trials
Ongoing research and clinical trials are focused on identifying new therapeutic targets and developing novel treatments for PMR. These efforts are expected to lead to breakthroughs in the coming years.
Strategic Collaborations
Pharmaceutical companies are entering into strategic collaborations with research institutions and healthcare providers to accelerate the development of new treatments. These collaborations are facilitating the exchange of knowledge and resources.
Technological Innovations
Technological innovations in drug delivery systems and diagnostic tools are enhancing the management of PMR. For instance, the development of long-acting corticosteroids and advanced imaging techniques is improving patient outcomes.
Polymyalgia Rheumatica Treatment Market Scope
The scope of the polymyalgia rheumatica treatment market is broad, encompassing various aspects of disease management. This includes:
Disease Management
Effective management of PMR involves a combination of pharmacological and non-pharmacological approaches. Medications such as corticosteroids are the mainstay of treatment, while physical therapy and lifestyle modifications play supportive roles.
Patient Education
Educating patients about PMR and its management is crucial for improving treatment adherence and outcomes. Healthcare providers are focusing on providing comprehensive education to patients and their caregivers.
Healthcare Infrastructure
The availability of advanced healthcare infrastructure is essential for the effective diagnosis and treatment of PMR. Investments in healthcare facilities and diagnostic tools are enhancing the management of the disease.
Market Access
Ensuring market access to PMR treatments is crucial for addressing the unmet needs of patients. Governments and healthcare organizations are working to improve access to affordable and effective treatments.
Polymyalgia Rheumatica Treatment Market Analysis
SWOT Analysis
Strengths
- Effective Treatments Available: The availability of effective treatments such as corticosteroids and biologics.
- Growing Awareness: Increasing awareness about PMR and its symptoms.
Weaknesses
- Side Effects of Treatments: Long-term use of corticosteroids can lead to significant side effects.
- High Cost of Treatment: The high cost associated with PMR treatment can be a barrier for some patients.
Opportunities
- Advancements in Research: Ongoing research and development activities are expected to lead to new and improved treatments.
- Increasing Healthcare Investments: Rising healthcare investments in developing regions.
Threats
- Regulatory Challenges: Stringent regulatory requirements in some regions.
- Competition: The presence of numerous players in the market leading to intense competition.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the polymyalgia rheumatica treatment market. The pandemic has disrupted healthcare systems worldwide, affecting the diagnosis and treatment of PMR.
Disruptions in Healthcare Services
The pandemic led to disruptions in healthcare services, with many healthcare facilities prioritizing COVID-19 patients. This resulted in delays in the diagnosis and treatment of PMR, negatively impacting patient outcomes.
Impact on Clinical Trials
The pandemic also affected clinical trials for new PMR treatments. Many trials were delayed or suspended, slowing the progress of research and development activities.
Increased Use of Telemedicine
The pandemic accelerated the adoption of telemedicine, enabling patients to consult healthcare providers remotely. This has improved access to care for PMR patients, particularly those in remote areas.
Supply Chain Challenges
The global supply chain for pharmaceuticals was disrupted during the pandemic, leading to shortages of medications in some regions. This impacted the availability of PMR treatments.
Key Players in the Polymyalgia Rheumatica Treatment Market
Sanofi SA
Sanofi is a global pharmaceutical company that develops and markets a wide range of medications, including treatments for PMR. The company is focused on innovation and has a strong pipeline of drugs in development.
Apotex Corporation
Apotex is a leading generic pharmaceutical company that offers a variety of medications for the treatment of PMR. The company is committed to providing affordable and accessible treatments to patients worldwide.
GlaxoSmithKline plc
GlaxoSmithKline (GSK) is a major player in the PMR treatment market. The company has a robust portfolio of medications and is actively involved in research and development activities.
AbbVie Inc.
AbbVie is a global biopharmaceutical company known for its innovative treatments. The company is focused on developing biologics and targeted therapies for PMR and other rheumatic diseases.
Horizon Therapeutics plc
Horizon Therapeutics is a biopharmaceutical company dedicated to improving the lives of patients with rare and rheumatic diseases. The company has a strong presence in the PMR treatment market.
Others
Several other companies are also active in the PMR treatment market, including small and mid-sized pharmaceutical companies. These players are contributing to the market’s growth by developing and marketing innovative treatments.
Frequently Asked Questions (FAQ)
The global polymyalgia rheumatica treatment market attained a value of about USD 203.73 million in 2023. The market is further expected to grow in the forecast period of 2024-2032 at a CAGR of 4.7% to reach nearly USD 308.68 million by 2032. This blog post will delve into various aspects of the polymyalgia rheumatica treatment market, providing an in-depth analysis of its dynamics, trends, segmentation, growth prospects, recent developments, market scope, and the impact of COVID-19.
Polymyalgia Rheumatica Treatment Market Overview
Polymyalgia rheumatica (PMR) is an inflammatory disorder that causes muscle pain and stiffness, particularly in the shoulders and hips. It primarily affects older adults and can significantly impact the quality of life. The treatment market for PMR includes a range of medications aimed at reducing inflammation and alleviating symptoms.
Key Market Drivers
- Aging Population: With the increasing global population of older adults, the prevalence of polymyalgia rheumatica is rising, driving demand for effective treatments.
- Advancements in Medical Research: Continuous research and development activities in the field of rheumatology are leading to the introduction of new and more effective treatments.
- Increased Healthcare Awareness: Growing awareness about PMR and its symptoms is prompting more people to seek medical attention, thereby expanding the market.
Market Restraints
- Side Effects of Medications: Long-term use of corticosteroids, the primary treatment for PMR, can lead to significant side effects, which may hinder market growth.
- High Cost of Treatment: The high cost associated with PMR treatment can be a barrier, particularly in low- and middle-income countries.
Polymyalgia Rheumatica Treatment Market Dynamics
The polymyalgia rheumatica treatment market is influenced by various factors that shape its growth trajectory. Understanding these dynamics is crucial for stakeholders to make informed decisions.
Demand and Supply Dynamics
- Demand Side: The increasing prevalence of PMR and rising awareness about the disease are key factors driving demand. Additionally, the development of more effective and safer medications is also contributing to market growth.
- Supply Side: Pharmaceutical companies are focusing on expanding their product portfolios to include innovative PMR treatments. The availability of advanced diagnostic tools is also facilitating the early diagnosis and treatment of PMR.
Technological Advancements
Technological advancements in the field of rheumatology are playing a pivotal role in the treatment of PMR. The development of biologics and targeted therapies has revolutionized the treatment landscape, offering new hope to patients who do not respond well to traditional therapies.
Regulatory Environment
The regulatory environment for PMR treatments varies across regions. Stringent regulations in developed countries ensure the safety and efficacy of medications, while less stringent regulations in developing regions may pose challenges for market entry.
External Polymyalgia Rheumatica Treatment Market Trends
Several external trends are shaping the polymyalgia rheumatica treatment market. These trends include:
Increasing R&D Investments
Pharmaceutical companies are investing heavily in research and development to discover new treatments for PMR. This trend is expected to continue, leading to the introduction of more effective and safer medications.
Collaborations and Partnerships
Collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare providers are becoming increasingly common. These collaborations are aimed at accelerating the development of new treatments and improving patient outcomes.
Patient-Centric Approaches
There is a growing emphasis on patient-centric approaches in the treatment of PMR. Healthcare providers are focusing on personalized treatment plans that cater to the specific needs of individual patients.
Digital Health Technologies
The integration of digital health technologies, such as telemedicine and mobile health apps, is enhancing the management of PMR. These technologies enable patients to monitor their symptoms and communicate with healthcare providers remotely, improving access to care.
Polymyalgia Rheumatica Treatment Market Segmentation
The polymyalgia rheumatica treatment market can be segmented based on several criteria, including drug type, route of administration, distribution channel, and region.
By Drug Type
- Corticosteroids: Prednisone is the most commonly prescribed corticosteroid for PMR treatment. Other corticosteroids include methylprednisolone and prednisolone.
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs such as ibuprofen and naproxen are used to relieve pain and inflammation.
- Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate is sometimes used in patients who do not respond well to corticosteroids.
- Biologics: Biologic agents like tocilizumab are being explored for their potential in treating PMR.
By Route of Administration
- Oral: The most common route for administering corticosteroids and NSAIDs.
- Injectable: Injectable forms of corticosteroids and biologics are also used in certain cases.
By Distribution Channel
- Hospitals: Hospitals are the primary distribution channel for PMR treatments, particularly for severe cases.
- Retail Pharmacies: Retail pharmacies play a significant role in the distribution of oral medications.
- Online Pharmacies: The rise of online pharmacies is providing patients with convenient access to medications.
By Region
- North America: North America is the largest market for PMR treatments, driven by a high prevalence of the disease and advanced healthcare infrastructure.
- Europe: Europe is another significant market, with a large aging population and increasing awareness about PMR.
- Asia-Pacific: The Asia-Pacific region is expected to witness the fastest growth, owing to rising healthcare investments and improving diagnostic capabilities.
- Latin America: The market in Latin America is growing steadily, supported by increasing healthcare expenditure.
- Middle East and Africa: The market in this region is relatively small but is expected to grow as healthcare access improves.
Polymyalgia Rheumatica Treatment Market Growth
The polymyalgia rheumatica treatment market is poised for significant growth over the forecast period. Several factors contribute to this growth:
Increasing Prevalence of PMR
The aging global population is leading to a rise in the prevalence of PMR. As the population of older adults increases, so does the number of individuals diagnosed with PMR, driving demand for treatments.
Advancements in Treatment Options
Advancements in medical research are leading to the development of new and more effective treatments for PMR. The introduction of biologics and targeted therapies is expected to drive market growth.
Rising Healthcare Expenditure
Rising healthcare expenditure in both developed and developing regions is facilitating better access to PMR treatments. Governments and private sector players are investing in healthcare infrastructure, improving the diagnosis and treatment of PMR.
Growing Awareness
Increasing awareness about PMR and its symptoms is prompting more individuals to seek medical attention. Public health campaigns and educational initiatives are playing a crucial role in raising awareness.
Improved Diagnostic Capabilities
Advancements in diagnostic tools are enabling early and accurate diagnosis of PMR. Early diagnosis is crucial for effective treatment and better patient outcomes.
Recent Developments in the Polymyalgia Rheumatica Treatment Market
New Drug Approvals
The market has witnessed several new drug approvals in recent years. These new treatments are offering better efficacy and safety profiles, providing patients with more options.
Research and Clinical Trials
Ongoing research and clinical trials are focused on identifying new therapeutic targets and developing novel treatments for PMR. These efforts are expected to lead to breakthroughs in the coming years.
Strategic Collaborations
Pharmaceutical companies are entering into strategic collaborations with research institutions and healthcare providers to accelerate the development of new treatments. These collaborations are facilitating the exchange of knowledge and resources.
Technological Innovations
Technological innovations in drug delivery systems and diagnostic tools are enhancing the management of PMR. For instance, the development of long-acting corticosteroids and advanced imaging techniques is improving patient outcomes.
Polymyalgia Rheumatica Treatment Market Scope
The scope of the polymyalgia rheumatica treatment market is broad, encompassing various aspects of disease management. This includes:
Disease Management
Effective management of PMR involves a combination of pharmacological and non-pharmacological approaches. Medications such as corticosteroids are the mainstay of treatment, while physical therapy and lifestyle modifications play supportive roles.
Patient Education
Educating patients about PMR and its management is crucial for improving treatment adherence and outcomes. Healthcare providers are focusing on providing comprehensive education to patients and their caregivers.
Healthcare Infrastructure
The availability of advanced healthcare infrastructure is essential for the effective diagnosis and treatment of PMR. Investments in healthcare facilities and diagnostic tools are enhancing the management of the disease.
Market Access
Ensuring market access to PMR treatments is crucial for addressing the unmet needs of patients. Governments and healthcare organizations are working to improve access to affordable and effective treatments.
Polymyalgia Rheumatica Treatment Market Analysis
SWOT Analysis
Strengths
- Effective Treatments Available: The availability of effective treatments such as corticosteroids and biologics.
- Growing Awareness: Increasing awareness about PMR and its symptoms.
Weaknesses
- Side Effects of Treatments: Long-term use of corticosteroids can lead to significant side effects.
- High Cost of Treatment: The high cost associated with PMR treatment can be a barrier for some patients.
Opportunities
- Advancements in Research: Ongoing research and development activities are expected to lead to new and improved treatments.
- Increasing Healthcare Investments: Rising healthcare investments in developing regions.
Threats
- Regulatory Challenges: Stringent regulatory requirements in some regions.
- Competition: The presence of numerous players in the market leading to intense competition.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the polymyalgia rheumatica treatment market. The pandemic has disrupted healthcare systems worldwide, affecting the diagnosis and treatment of PMR.
Disruptions in Healthcare Services
The pandemic led to disruptions in healthcare services, with many healthcare facilities prioritizing COVID-19 patients. This resulted in delays in the diagnosis and treatment of PMR, negatively impacting patient outcomes.
Impact on Clinical Trials
The pandemic also affected clinical trials for new PMR treatments. Many trials were delayed or suspended, slowing the progress of research and development activities.
Increased Use of Telemedicine
The pandemic accelerated the adoption of telemedicine, enabling patients to consult healthcare providers remotely. This has improved access to care for PMR patients, particularly those in remote areas.
Supply Chain Challenges
The global supply chain for pharmaceuticals was disrupted during the pandemic, leading to shortages of medications in some regions. This impacted the availability of PMR treatments.
Key Players in the Polymyalgia Rheumatica Treatment Market
Sanofi SA
Sanofi is a global pharmaceutical company that develops and markets a wide range of medications, including treatments for PMR. The company is focused on innovation and has a strong pipeline of drugs in development.
Apotex Corporation
Apotex is a leading generic pharmaceutical company that offers a variety of medications for the treatment of PMR. The company is committed to providing affordable and accessible treatments to patients worldwide.
GlaxoSmithKline plc
GlaxoSmithKline (GSK) is a major player in the PMR treatment market. The company has a robust portfolio of medications and is actively involved in research and development activities.
AbbVie Inc.
AbbVie is a global biopharmaceutical company known for its innovative treatments. The company is focused on developing biologics and targeted therapies for PMR and other rheumatic diseases.
Horizon Therapeutics plc
Horizon Therapeutics is a biopharmaceutical company dedicated to improving the lives of patients with rare and rheumatic diseases. The company has a strong presence in the PMR treatment market.
Others
Several other companies are also active in the PMR treatment market, including small and mid-sized pharmaceutical companies. These players are contributing to the market’s growth by developing and marketing innovative treatments.
Frequently Asked Questions (FAQ)
What is polymyalgia rheumatica (PMR)?
Polymyalgia rheumatica (PMR) is an inflammatory disorder that causes muscle pain and stiffness, particularly in the shoulders and hips. It primarily affects older adults.
What are the common treatments for PMR?
The primary treatment for PMR is corticosteroids, such as prednisone. Other treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologics.
What factors are driving the growth of the PMR treatment market?
Key factors driving the market’s growth include the increasing prevalence of PMR, advancements in medical research, rising healthcare expenditure, growing awareness about the disease, and improved diagnostic capabilities.
How has the COVID-19 pandemic impacted the PMR treatment market?
The COVID-19 pandemic has disrupted healthcare services, clinical trials, and the global supply chain for pharmaceuticals. However, it has also accelerated the adoption of telemedicine, improving access to care for PMR patients.
Who are the key players in the PMR treatment market?
Key players in the market include Sanofi SA, Apotex Corporation, GlaxoSmithKline plc, AbbVie Inc., Horizon Therapeutics plc, and several other pharmaceutical companies.
What are the challenges facing the PMR treatment market?
Challenges include the side effects of long-term corticosteroid use, high treatment costs, regulatory challenges, and intense competition among market players.
What are the recent developments in the PMR treatment market?
Recent developments include new drug approvals, ongoing research and clinical trials, strategic collaborations, and technological innovations in drug delivery and diagnostics.
What is the market outlook for PMR treatments?
The PMR treatment market is expected to grow significantly over the forecast period, driven by the increasing prevalence of the disease, advancements in treatment options, rising healthcare expenditure, and growing awareness about PMR.
Polymyalgia rheumatica (PMR) is an inflammatory disorder that causes muscle pain and stiffness, particularly in the shoulders and hips. It primarily affects older adults.
What are the common treatments for PMR?
The primary treatment for PMR is corticosteroids, such as prednisone. Other treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologics.
What factors are driving the growth of the PMR treatment market?
Key factors driving the market’s growth include the increasing prevalence of PMR, advancements in medical research, rising healthcare expenditure, growing awareness about the disease, and improved diagnostic capabilities.
How has the COVID-19 pandemic impacted the PMR treatment market?
The COVID-19 pandemic has disrupted healthcare services, clinical trials, and the global supply chain for pharmaceuticals. However, it has also accelerated the adoption of telemedicine, improving access to care for PMR patients.
Who are the key players in the PMR treatment market?
Key players in the market include Sanofi SA, Apotex Corporation, GlaxoSmithKline plc, AbbVie Inc., Horizon Therapeutics plc, and several other pharmaceutical companies.
What are the challenges facing the PMR treatment market?
Challenges include the side effects of long-term corticosteroid use, high treatment costs, regulatory challenges, and intense competition among market players.
What are the recent developments in the PMR treatment market?
Recent developments include new drug approvals, ongoing research and clinical trials, strategic collaborations, and technological innovations in drug delivery and diagnostics.
What is the market outlook for PMR treatments?
The PMR treatment market is expected to grow significantly over the forecast period, driven by the increasing prevalence of the disease, advancements in treatment options, rising healthcare expenditure, and growing awareness about PMR.
Media Contact:
Company Name: Claight Corporation
Contact Person: Mark, Business Consultant
Email: sales@expertmarketresearch.com
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com